share_log

Stifel Maintains Hold on Aclaris Therapeutics, Lowers Price Target to $1

Benzinga ·  Dec 18, 2023 09:22

Stifel analyst Alex Thompson maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Hold and lowers the price target from $2 to $1.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment